| MYRIAD GENETICS DL-,01 |
| USA |
| Gesundheit |
| US62855J1043 / 897518 |
| MYD (Frankfurt) / MYGN (NASDAQ) |
| FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN |
| - |
| https://myriad.com/ |
|
Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renow..
>Volltext.. |
| 346.77 Mio. EUR |
| 398.08 Mio. EUR |
| 700.29 Mio. EUR |
| -12.83 Mio. EUR |
| -310.78 Mio. EUR |
| -3.36 EUR |
| 178.19 Mio. EUR |
| 127.06 Mio. EUR |
| 1.53 Mio. EUR |
| 1.12 |
| -13.24% |
| -153.34% |
| - |
| - |
| - |
| - |
| MYRIAD GENETICS |
| 26.02.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|